ClinicalTrials.gg
CompletedNCT01565850Updated Apr 11, 2016Results posted

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

A Phase 2 interventional study of D/C/F/TAF and DRV in Acquired Immunodeficiency Syndrome and HIV Infections, sponsored by Gilead Sciences. Completed at 44 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-11.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. tenofovir alafenamide · Acquired Immunodeficiency Syndrome.

Enrollment
6th of 21
153 · median 80
Started
2012
the only one that year
Phase 2
3 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
6 of 21
Gilead Sciences

Among the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 2nd registered.

Acquired Immunodeficiency Syndrome

3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

1 of the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, or all of them as a file.
02

Study summary

This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA \< 50 copies/mL at Week 24.

03

Conditions studied

  • Acquired Immunodeficiency Syndrome
  • HIV Infections

Keywords

  • HIV-1
  • HIV
  • Treatment-Naive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥ 18 years) males or non-pregnant females
  • Ability to understand and sign a written form
  • General medical condition which does not interfere with the assessments and the completion of the trial
  • Plasma -1 RNA levels ≥ 5,000 copies/mL
  • > 50 cells/µL
  • Treatment-naive: No prior use of any approved or experimental anti-HIV drug for any length of time
  • Screening genotype report must show sensitivity to DRV, TDF and FTC
  • Normal
  • Adequate renal function: Estimated ≥ 70 mL/min according to the formula
  • Hepatic transaminases ≤ 2.5 x (ULN)
  • Total ≤ 1.5 mg/dL
  • Serum amylase ≤ 5 x ULN
  • Adequate hematologic function
  • Normal thyroid-stimulating hormone (TSH)
  • Females of must have a negative serum pregnancy test
  • Females of childbearing potential must agree to utilize highly effective methods from screening throughout the duration of study treatment and for 30 days following the last dose of study drugs
  • Female subjects who are must have documentation of cessation of menses for ≥ 12 months and hormonal failure
  • Female subjects who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level test
  • Male subjects must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 90 days following discontinuation of medicinal product

Exclusion criteria

Exclusion Criteria:

  • A new AIDS defining condition diagnosed within the 30 days prior to screening
  • surface antigen positive
  • antibody positive
  • Proven acute hepatitis in the 30 days prior to study entry
  • Have a history or experiencing decompensated cirrhosis
  • Current alcohol or substance use that potentially interferes with study compliance
  • Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements
  • History of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma
  • Females who are breastfeeding
  • Positive serum pregnancy test (female of )
  • Female subjects who utilize non-estrogen hormonal as one of their birth control methods must have used the same method for at least three months prior to study dosing
  • Have an implanted defibrillator or pacemaker
  • Active, serious infections (other than -1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline
  • Participation in any other clinical trial without prior approval is prohibited while participating in this trial
  • Receiving ongoing therapy with any of the disallowed medications, including drugs not to be used with darunavir and cobicistat
  • Note: darunavir is a sulfonamide. Participants who previously experienced a sulfonamide allergy will be allowed to enter the trial. To date, no potential for cross sensitivity between drugs in the sulfonamide class and darunavir has been identified in patients participating in Phase 2 and Phase 3 trials.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    D/C/F/TAF

    D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo

    Drug: D/C/F/TAF · Drug: DRV Placebo · Drug: COBI Placebo · Drug: FTC/TDF Placebo

  • Active comparator
    DRV+COBI+FTC/TDF

    DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo

    Drug: DRV · Drug: COBI · Drug: FTC/TDF · Drug: D/C/F/TAF Placebo

Interventions

  • DrugD/C/F/TAF

    Drug page: Tenofovir alafenamide

    DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily

  • DrugDRV

    DRV 800 mg (2 × 400 mg tablets) administered orally once daily

    Also known as: Prezista®

  • DrugCOBI

    COBI 150 mg tablet administered orally once daily

    Also known as: Tybost®, GS-9350

  • DrugFTC/TDF

    FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily

    Also known as: Truvada®

  • DrugD/C/F/TAF Placebo

    D/C/F/TAF placebo tablet administered orally once daily

  • DrugDRV Placebo

    DRV placebo tablet administered orally once daily

  • DrugCOBI Placebo

    COBI placebo tablet administered orally once daily

  • DrugFTC/TDF Placebo

    FTC/TDF placebo tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24

    The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

    The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  2. Change From Baseline in HIV-1 RNA at Week 24

    Time frame: Baseline; Week 24

  3. Change From Baseline in HIV-1 RNA at Week 48

    Time frame: Baseline; Week 48

  4. Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline; Week 24

  5. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

07

Results

Posted Apr 11, 2016
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at study sites in the United States (including Puerto Rico). The first participant was screened on 16 April 2012. The last study visit occurred on 19 February 2014.

Participant flow — Overall Study
MilestoneD/C/F/TAFDRV+COBI+FTC/TDF
Started10350
Completed8342
Not completed208
Withdrew: Adverse event01
Withdrew: Lost to follow-up124
Withdrew: Investigator's discretion21
Withdrew: Participant noncompliance20
Withdrew: Withdrew consent42

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24

The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
percentage of participantsD/C/F/TAFDRV+COBI+FTC/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 2474.874.0
Statistical analysis
  • D/C/F/TAF vs DRV+COBI+FTC/TDF · Cochran-Mantel-Haenszel · p = 0.64 (The p-value for the superiority test comparing the percentages of virologic success was from the Cochran-Mantel-Haenszel test stratified by baseline HIV-1 RNA and race strata.) · Difference in proportions: 3.3 · 95% CI -11.4 to 18.1The difference in percentages of virologic success and its 95% confidence interval (CI) were calculated based on baseline HIV-1 RNA and race stratum-adjusted Mantel-Haenszel proportion.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
percentage of participantsD/C/F/TAFDRV+COBI+FTC/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 4876.784.0
Statistical analysis
  • D/C/F/TAF vs DRV+COBI+FTC/TDF · Cochran-Mantel-Haenszel · p = 0.35 (The p-value for the superiority test comparing the percentages of virologic success was from the Cochran-Mantel-Haenszel test stratified by baseline HIV-1 RNA and race strata.) · Difference in proportions: -6.2 · 95% CI -19.9 to 7.4The difference in percentages of virologic success and its 95% CI were calculated based on baseline HIV-1 RNA and race stratum-adjusted Mantel-Haenszel proportion.
SecondaryChange From Baseline in HIV-1 RNA at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · log10 copies/mL
Change From Baseline in HIV-1 RNA at Week 24
log10 copies/mLD/C/F/TAFDRV+COBI+FTC/TDF
Change From Baseline in HIV-1 RNA at Week 24-3.20 ± 0.653-3.18 ± 0.416
Statistical analysis
  • D/C/F/TAF vs DRV+COBI+FTC/TDF · ANOVA · p = 0.67 (The p-value, difference in least squares mean (LSM), and its 95% CI were from ANOVA model with baseline HIV-1 RNA level (≤ 100,000 or \> 100,000 copies/mL) and race (Black or non-Black) as fixed effects in the model.) · Difference in lsm: 0.04 · 95% CI -0.14 to 0.21
SecondaryChange From Baseline in HIV-1 RNA at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · log10 copies/mL
Change From Baseline in HIV-1 RNA at Week 48
log10 copies/mLD/C/F/TAFDRV+COBI+FTC/TDF
Change From Baseline in HIV-1 RNA at Week 48-3.27 ± 0.668-3.26 ± 0.521
Statistical analysis
  • D/C/F/TAF vs DRV+COBI+FTC/TDF · ANOVA · p = 0.50 (The p-value, difference in LSM, and its 95% CI were from ANOVA model with baseline HIV-1 RNA level (≤ 100,000 or \> 100,000 copies/mL) and race (Black or non-Black) as fixed effects in the model.) · Difference in lsm: 0.06 · 95% CI -0.11 to 0.23
SecondaryChange From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 24
cells/µLD/C/F/TAFDRV+COBI+FTC/TDF
Change From Baseline in CD4+ Cell Count at Week 24186 ± 137.9139 ± 185.8
Statistical analysis
  • D/C/F/TAF vs DRV+COBI+FTC/TDF · ANOVA · p = 0.11 (The p-value, difference in LSM, and its 95% CI were from ANOVA model with baseline HIV-1 RNA level (≤ 100,000 or \> 100,000 copies/mL) and race (Black or non-Black) as fixed effects in the model.) · Difference in lsm: 45 · 95% CI -10 to 101
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLD/C/F/TAFDRV+COBI+FTC/TDF
Change From Baseline in CD4+ Cell Count at Week 48231 ± 141.9212 ± 151.5
Statistical analysis
  • D/C/F/TAF vs DRV+COBI+FTC/TDF · ANOVA · p = 0.50 (The p-value, difference in LSM, and its 95% CI were from ANOVA model with baseline HIV-1 RNA level (≤ 100,000 or \> 100,000 copies/mL) and race (Black or non-Black) as fixed effects in the model.) · Difference in lsm: 18 · 95% CI -35 to 72

Adverse events

Collected over Baseline through end of study drug treatment (average exposure: D/C/F/TAF group = 61.7 weeks; DRV+COBI+FTC/TDF group = 66.1 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
D/C/F/TAF—5/103 (4.9%)77/103 (74.8%)
DRV+COBI+FTC/TDF—2/50 (4%)40/50 (80%)
Most frequent serious events
Most frequent serious events
EventD/C/F/TAFDRV+COBI+FTC/TDF
BronchitisInfections and infestations0/1031/50
Bronchitis viralInfections and infestations0/1031/50
PneumoniaInfections and infestations0/1031/50
Renal tubular disorderRenal and urinary disorders0/1031/50
Diarrhoea haemorrhagicGastrointestinal disorders1/1030/50
HypersensitivityImmune system disorders1/1030/50
CellulitisInfections and infestations1/1030/50
Psychotic disorderPsychiatric disorders1/1030/50
Substance abusePsychiatric disorders1/1030/50
Most frequent other events
Showing 10 of 29
Most frequent other events
EventD/C/F/TAFDRV+COBI+FTC/TDF
DiarrhoeaGastrointestinal disorders22/10313/50
FatigueGeneral disorders14/1039/50
Upper respiratory tract infectionInfections and infestations16/1037/50
NauseaGastrointestinal disorders13/1035/50
FlatulenceGastrointestinal disorders5/1036/50
RashSkin and subcutaneous tissue disorders12/1034/50
VomitingGastrointestinal disorders4/1035/50
Vitamin D deficiencyMetabolism and nutrition disorders2/1035/50
Pain in extremityMusculoskeletal and connective tissue disorders8/1035/50
BronchitisInfections and infestations9/1032/50

Baseline characteristics

Safety Analysis Set: participants who were randomized and received at least one dose of study drug

Age, Continuous
Age, Continuous(years)D/C/F/TAFDRV+COBI+FTC/TDFTotal
Mean35 ± 11.337 ± 10.935 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)D/C/F/TAFDRV+COBI+FTC/TDFTotal
Female8311
Male9547142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)D/C/F/TAFDRV+COBI+FTC/TDFTotal
Hispanic or Latino23932
Not Hispanic or Latino8041121
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)D/C/F/TAFDRV+COBI+FTC/TDFTotal
White623092
Black or African American361753
Asian213
Native Hawaiian or Other Pacific Islander112
Other213
Region of Enrollment
Region of Enrollment(participants)D/C/F/TAFDRV+COBI+FTC/TDFTotal
United States10350153
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)D/C/F/TAFDRV+COBI+FTC/TDFTotal
Mean4.70 ± 0.5164.65 ± 0.5144.68 ± 0.515
HIV-1 RNA Category
HIV-1 RNA Category(participants)D/C/F/TAFDRV+COBI+FTC/TDFTotal
≤ 100,000 copies/mL8043123
> 100,000 to ≤ 400,000 copies/mL17522
> 400,000 copies/mL628
CD4 Cell Count
CD4 Cell Count(cells/µL)D/C/F/TAFDRV+COBI+FTC/TDFTotal
Mean395 ± 169.3464 ± 261.6417 ± 205.7

1 further baseline measures are reported on the registry.

08

Study locations

44 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • AHF Research Center
    Beverly Hills, California 90211, United States
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • Peter J. Ruane, MD, Inc.
    Los Angeles, California 90036, United States
  • Anthony Mills MD, Inc
    Los Angeles, California 90069, United States
  • Orange Coast Medical Group
    Newport Beach, California 92663, United States
  • Alta Bates Summit Medical Center, East Bay AIDS Center
    Oakland, California 94609, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Kaiser Permanente Medical Group
    Sacramento, California 95825, United States
  • La Playa Medical Group and Clinical Research
    San Diego, California 92103, United States
  • Kasier Permanente Medical Center
    San Francisco, California 94118, United States
  • TPMG--Clinical Trials Unit
    San Francisco, California 94118, United States
  • Apex Research
    Denver, Colorado 80209, United States
  • Denver Infectious Disease Consultants, PLLC
    Denver, Colorado 80220, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia 20009, United States
  • Whitman-Walker Health
    Washington, District of Columbia 20009, United States
  • Capital Medical Associates, PC
    Washington, District of Columbia 20036, United States
  • Gary J. Richmond,M.D.,P.A.
    Fort Lauderdale, Florida 33316, United States
  • Wohlfeiler, Piperato and Associates, LLC
    Miami Beach, Florida 33139, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • IDOCF/ValuhealthMD, LLC
    Orlando, Florida 32806, United States
  • St. Joseph's Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University Mercer Medicine
    Macon, Georgia 31201, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Community Research Initiative (CRI)
    Boston, Massachusetts 02215, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Central West Clinical Research Inc
    St. Louis, Missouri 63108, United States
  • North Shore University Hospital / Division of Infectious Diseases
    Manhasset, New York 11030, United States
  • Weill Cornell Medical College
    New York, New York 10011, United States
  • ID Consultants, P.A.
    Charlotte, North Carolina 28209, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of South Carolina School of Medicine Division of Infectious Disease
    Columbia, South Carolina 29203, United States
  • Southwest Infectious Disease Clinical Research Inc
    Dallas, Texas 75219, United States
  • Tarrant County Infectious Disease Associates
    Fort Worth, Texas 76104, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Gordon E. Crofoot, MD., PA
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • CARE-ID
    Annandale, Virginia 22003, United States
  • Peter Shalit, M.D.
    Seattle, Washington 98104, United States
  • Clinical Research Puerto Rico
    San Juan, 00909, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jan 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 3 years 3 months after primary completion. A results delay was requested in Nov 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2012
First posted
Mar 29, 2012
Start
Apr 2012
Primary completionActual
Jan 2013
CompletionActual
Feb 2014
Results delay requested
Nov 25, 2013
Results first posted
Apr 11, 2016
Last update
Apr 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01565850
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 29, 2012
Start date
Apr 2012
Primary completion
Jan 2013
Completion
Feb 2014
Results posted
Apr 11, 2016
Last update
Apr 11, 2016

Study contacts

Moupali Das, MD, MPH
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion